Home » Posts tagged with » Novartis
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business

Novartis’ Sandoz to acquire Aspen’s Japanese pharma business

Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]

Novartis bags Beovu FDA approval for wet AMD

Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu (brolucizumab) injection for wet age-related macular degeneration (AMD). Also called RTH258, Beovu is now the first FDA approved anti-VEGF which is said to deliver greater fluid resolution compared to aflibercept. […]

Continue reading …
Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis. As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will […]

Continue reading …
Novartis to acquire IFM Tre with eye on immunomodulatory drugs

Novartis acquisition of IFM Tre : Novartis has signed a deal worth up to $1.575 billion to acquire US biopharma company IFM Tre from IFM Therapeutics. Novartis acquisition of IFM Tre The acquisition of the US biopharma company, which was only launched last year, is expected to add certain immunomodulatory drugs to the Swiss pharma […]

Continue reading …
Novartis’ Mayzent approved by FDA for treatment of relapsing forms of MS

Mayzent FDA approval : The US Food and Drug Administration (FDA) has approved Swiss pharma company Novartis’ Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Mayzent FDA approval The latest FDA approved Novartis MS drug can now be used for the treatment of secondary progressive multiple sclerosis (SPMS) with […]

Continue reading …
Blackstone Life Sciences, Novartis launch Anthos Therapeutics

Blackstone Life Sciences, a private investment platform, has joined forces with Swiss drug maker Novartis to launch a new biopharma company called Anthos Therapeutics, which will focus on developing drugs for high-risk cardiovascular patients. Anthos Therapeutics, which will be headquartered in Cambridge, Massachusetts, is backed by a capital of $250 million from Blackstone Life Sciences. […]

Continue reading …
Novartis gets Egaten FDA approval for fascioliasis treatment

Pharma regulatory news : Novartis has secured Egaten FDA approval for fascioliasis treatment in patients, aged six years and older. Fascioliasis is a neglected tropical disease, commonly known as liver fluke infestation. The disease is said to affect millions of people across the world. Fascioliasis is caused by two species of parasitic flatworms – Fasciola […]

Continue reading …
Clinigen to buy US rights to Proleukin from Novartis

British pharma company Clinigen has agreed to buy the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Swiss pharma company Novartis in an all-cash transaction that could be worth up to $210 million. Proleukin is an FDA approved drug for metastatic melanoma and metastatic renal cell carcinoma. Clinigen has agreed to make the payments […]

Continue reading …
Novartis proposes to acquire French CDMO CellforCure from LFB

Novartis has proposed to acquire French contract development and manufacturing organizations (French CDMO) CellforCure from LFB for an undisclosed price. CellforCure is engaged in producing cell and gene therapies across Europe. The deal proposed by Novartis includes the cell and gene manufacturing facility in Les Ulis near Paris and the related adjacent land. If the […]

Continue reading …
Novartis breast cancer drug Kisqali plus endocrine therapy extends PFS

Novartis breast cancer drug Kisqali (ribociclib) plus endocrine therapy has succeeded in extending progression-free survival (PFS) compared to only endocrine therapy in three phase 3 MONALEESA trials. The findings come from the Swiss pharma company’s release of data from subgroup analyses of the three pivotal trials in pre-, peri- and postmenopausal women, irrespective of the […]

Continue reading …
Page 1 of 3123